multiple-myeloma

Documents about multiple-myeloma

• a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia#848310ClinicalTrials.gov
• A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan#859575ClinicalTrials.gov
• A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.#886305ClinicalTrials.gov
• New Developments in Myeloma Treatment and Response Assessment#304722HAL (France)
• UARK 2005-01 Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory Patients#872039ClinicalTrials.gov
• New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells#294460Gestión del Repositorio Documental de la Universidad de Salamanca
• A Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT)#805344ClinicalTrials.gov
• A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis#829247ClinicalTrials.gov
• A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma#871733ClinicalTrials.gov
• A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers#889114ClinicalTrials.gov
• Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma#460091ClinicalTrials.gov
• Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide#846713ClinicalTrials.gov
• VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma#873091ClinicalTrials.gov
• A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory#848861ClinicalTrials.gov
• A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma#863374ClinicalTrials.gov
• Traitement du Myélome Multiple par l’inhibition des facteurs Polycomb#156094HAL (France)
• Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM#296804Gestión del Repositorio Documental de la Universidad de Salamanca
• S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma#830616ClinicalTrials.gov
• Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts#852688ClinicalTrials.gov
• Cutting-Edge Technologies to Decode Tumor Microenvironment in Multiple Myeloma#461040IRIS
• GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5#807328ClinicalTrials.gov
• Skin Biopsies in Chemotherapy-Induced Neuropathy#813305ClinicalTrials.gov
• Familial Dysglobulinemia#858305ClinicalTrials.gov
• Optimal acquisition time of [⁶⁸Ga]Ga-PentixaFor PET/CT for initial staging of multiple myeloma: an ancillary study to the PentiMyelo protocol#288070HAL (France)
• Additional file 1 of Real-world evidence on infection risk in multiple myeloma treated with BiTEs and CAR-T cells: a meta-analysis#296753Figshare
• LNCRNA NEAT1 ORCHESTRATES A CERNA NETWORK GOVERNING CORE PATHWAYS OF PROLIFERATION AND CELLULAR DYNAMICS IN MULTIPLE MYELOMA#472068IRIS
• Raw mRNA sequencing and DNA methylation array data from multiple myeloma cells treated with vitamins D3 and K2 under normoxic and hypoxic conditions#666758RepOD Dataverse OAI Archive
• Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma#802146ClinicalTrials.gov
• Study of Thrombin Generation During the 3 First Cycles of Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma#826536ClinicalTrials.gov
• A Perspective Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial Treatment#885462ClinicalTrials.gov
• IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia#890940ClinicalTrials.gov
• A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)#992786ClinicalTrials.gov
• Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant#872560ClinicalTrials.gov
• Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma#833556ClinicalTrials.gov
• Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, for the Treatment of Patients With Relapsed Myeloma#857106ClinicalTrials.gov
• A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)#850165ClinicalTrials.gov
• Vaccine Therapy With or Without Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Multiple Myeloma Undergoing Donor Stem Cell Transplant#283041ClinicalTrials.gov
• Total Marrow Irradiation and High-dose Melphalan for Double Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma#871829ClinicalTrials.gov
• A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM)#873351ClinicalTrials.gov
• Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple Myeloma#886227ClinicalTrials.gov
• A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma#903274ClinicalTrials.gov
• Developing next generation immunomodulatory drugs and their combinations in multiple myeloma#242868Ora Oxford University Research
• A Pilot Bioequivalence Study of Pomalidomide#864295ClinicalTrials.gov
• Cevostamab Following CAR T Cell Therapy for RRMM#880182ClinicalTrials.gov
• RAT-HEMATO : Return to Work After Malignant Hemopathy#885928ClinicalTrials.gov
• Randomized Study of Digital Life Coaching in Myeloma Patients Undergoing Transplantation#890949ClinicalTrials.gov
• Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma#861392ClinicalTrials.gov
• A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease#876183ClinicalTrials.gov
• Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma#825946ClinicalTrials.gov
• Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL#802546ClinicalTrials.gov